Company intelligence / Profile preview

Trestle Biotherapeutics

San Diego, California, United Statestrestlebio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Trestle Biotherapeutics is developing implantable bioengineered kidney tissues for patients with end-stage renal disease. The company is in the preclinical stage, working on functional stem cell-based tissues designed to restore renal function sufficient to eliminate dialysis dependency. In 2023, they received a $1 million prize from the KidneyX Innovation Accelerator for their innovative approach[5][9].

Therapeutic areas: Nephrology
Modalities: Stem cell-derived tissuesbioengineered tissues
Industry: Biotech

Partnerships

Humacyte, Inc. (research collaboration announced March 2025)[2][7]

Beyond the preview

Go deeper on Trestle Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trestle Biotherapeutics.

Explore the full profile